SOL Capital Management CO Has $412,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

SOL Capital Management CO trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 41.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,818 shares of the medical instruments supplier’s stock after selling 1,300 shares during the period. SOL Capital Management CO’s holdings in Becton, Dickinson and Company were worth $412,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Sound Income Strategies LLC raised its position in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares in the last quarter. Central Pacific Bank Trust Division raised its holdings in shares of Becton, Dickinson and Company by 22.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 45 shares in the last quarter. Tompkins Financial Corp lifted its stake in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Birch Capital Management LLC boosted its holdings in Becton, Dickinson and Company by 0.4% in the third quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock worth $2,838,000 after purchasing an additional 48 shares in the last quarter. Finally, Radnor Capital Management LLC increased its position in Becton, Dickinson and Company by 1.7% during the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock worth $708,000 after buying an additional 48 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.3 %

Shares of BDX stock opened at $247.63 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $250.91. The firm’s fifty day simple moving average is $230.06 and its 200 day simple moving average is $233.66. The firm has a market capitalization of $71.82 billion, a P/E ratio of 41.69, a price-to-earnings-growth ratio of 1.79 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the business posted $3.42 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.68%. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 597 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was sold at an average price of $236.51, for a total value of $141,196.47. Following the completion of the sale, the executive vice president now directly owns 5,544 shares in the company, valued at approximately $1,311,211.44. This trade represents a 9.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP David Shan sold 500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler increased their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.